Free Trial

Atyr PHARMA (ATYR) Competitors

Atyr PHARMA logo
$3.24 -0.25 (-7.16%)
Closing price 03/26/2025 04:00 PM Eastern
Extended Trading
$3.26 +0.01 (+0.46%)
As of 03/26/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ATYR vs. AMPH, ARDX, EVO, ETNB, OCUL, GPCR, IOVA, CALT, AUPH, and GYRE

Should you be buying Atyr PHARMA stock or one of its competitors? The main competitors of Atyr PHARMA include Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), Ocular Therapeutix (OCUL), Structure Therapeutics (GPCR), Iovance Biotherapeutics (IOVA), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.

Atyr PHARMA vs.

Atyr PHARMA (NASDAQ:ATYR) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than Atyr PHARMA. MarketBeat recorded 9 mentions for Amphastar Pharmaceuticals and 4 mentions for Atyr PHARMA. Amphastar Pharmaceuticals' average media sentiment score of 0.72 beat Atyr PHARMA's score of -0.03 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Atyr PHARMA
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Amphastar Pharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

Atyr PHARMA has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

Amphastar Pharmaceuticals received 379 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 65.99% of users gave Amphastar Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Atyr PHARMAOutperform Votes
13
100.00%
Underperform Votes
No Votes
Amphastar PharmaceuticalsOutperform Votes
392
65.99%
Underperform Votes
202
34.01%

Amphastar Pharmaceuticals has higher revenue and earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atyr PHARMA$235K1,225.12-$50.39M-$0.87-3.72
Amphastar Pharmaceuticals$731.97M1.85$137.54M$3.069.27

Atyr PHARMA currently has a consensus price target of $18.60, indicating a potential upside of 474.07%. Amphastar Pharmaceuticals has a consensus price target of $43.50, indicating a potential upside of 53.33%. Given Atyr PHARMA's stronger consensus rating and higher probable upside, equities analysts clearly believe Atyr PHARMA is more favorable than Amphastar Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atyr PHARMA
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14
Amphastar Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Amphastar Pharmaceuticals has a net margin of 21.80% compared to Atyr PHARMA's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Atyr PHARMA's return on equity.

Company Net Margins Return on Equity Return on Assets
Atyr PHARMAN/A -79.44% -59.16%
Amphastar Pharmaceuticals 21.80%26.44%11.89%

Summary

Amphastar Pharmaceuticals beats Atyr PHARMA on 12 of the 19 factors compared between the two stocks.

Remove Ads
Get Atyr PHARMA News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATYR vs. The Competition

MetricAtyr PHARMABiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$287.90M$3.02B$5.62B$8.13B
Dividend YieldN/A1.54%4.56%4.00%
P/E Ratio-3.4529.3024.5419.09
Price / Sales1,225.12439.06386.7694.71
Price / CashN/A168.6838.1634.64
Price / Book2.104.066.974.36
Net Income-$50.39M-$71.95M$3.20B$247.23M
7 Day Performance-13.83%-4.96%-2.19%-0.34%
1 Month Performance-16.28%-9.73%3.14%-3.60%
1 Year PerformanceN/A-25.92%11.39%2.01%

Atyr PHARMA Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATYR
Atyr PHARMA
2.7624 of 5 stars
$3.24
-7.2%
$18.60
+474.1%
N/A$287.90M$235,000.00-3.4553Short Interest ↑
AMPH
Amphastar Pharmaceuticals
4.4144 of 5 stars
$27.69
+3.9%
$45.50
+64.3%
-34.3%$1.32B$731.97M9.231,620
ARDX
Ardelyx
4.3869 of 5 stars
$5.42
-0.9%
$10.95
+102.0%
-32.1%$1.29B$333.62M-33.8890
EVO
Evotec
1.7057 of 5 stars
$3.59
+2.3%
$5.93
+65.3%
-54.2%$1.27B$777.05M0.004,200
ETNB
89bio
2.8554 of 5 stars
$8.70
+2.7%
$27.56
+216.7%
-28.4%$1.27BN/A-2.9940
OCUL
Ocular Therapeutix
3.3732 of 5 stars
$7.94
+2.8%
$16.29
+105.1%
-16.6%$1.26B$63.72M-6.02230Positive News
GPCR
Structure Therapeutics
2.2782 of 5 stars
$21.79
+3.5%
$81.29
+273.0%
-52.6%$1.25BN/A-29.45136
IOVA
Iovance Biotherapeutics
4.319 of 5 stars
$3.74
+4.2%
$20.25
+441.4%
-75.5%$1.23B$164.07M-2.51500Analyst Revision
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
$39.25
-1.9%
N/A$1.19B$1.60B-21.62180
AUPH
Aurinia Pharmaceuticals
2.9605 of 5 stars
$8.40
+2.9%
$11.50
+36.9%
+72.8%$1.15B$235.13M-56.00300Positive News
GYRE
Gyre Therapeutics
0.2086 of 5 stars
$12.28
+1.4%
N/A-47.6%$1.15B$105.03M0.0040
Remove Ads

Related Companies and Tools


This page (NASDAQ:ATYR) was last updated on 3/27/2025 by MarketBeat.com Staff
From Our Partners